|
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Background:
Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This is a Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
Objectives:
 | Determine the maximum tolerated dose of erlotinib in patients with solid tumors and hepatic or renal dysfunction. | | Determine the pharmacokinetics of this drug in these patients. |
Location and Contact Information:
California
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, 94143-0128, United States; Recruiting
Alan Paul Venook, MD 415-476-2201
District of Columbia
Lombardi Cancer Center, Washington, District of Columbia, 20007, United States;
Recruiting
Edward P. Gelmann, MD 202-687-2490
gelmanne@georgetown.edu
Illinois
University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States;
Recruiting
Gini F. Fleming, MD 773-702-6712
Iowa
Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242-1009, United States;
Recruiting
Gerald H. Clamon, MD 319-356-1932
Maryland
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, 21201, United States;
Recruiting
Martin J. Edelman, MD 410-328-2703
medelman@umm.edu
New Hampshire
Norris Cotton Cancer Center, Lebanon, New Hampshire, 03756-0002, United States; Recruiting
Lionel D. Lewis, MD 603-650-6300
New York
Long Island Jewish Medical Center, New Hyde Park, New York, 11040, United States;
Recruiting
Marc Laurence Citron, MD 718-470-8930
citron@lij.edu
North Shore University Hospital, Manhasset, New York, 11030, United States;
Recruiting
Daniel R. Budman, MD 516-562-8958
North Carolina
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1082, United States;
Recruiting
David Duane Hurd, MD 336-716-2088
dhurd@wfubmc.edu
Ohio
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, 43210-1240, United States;
Recruiting
Clara D. Bloomfield, MD 614-293-7518
bloomfield-1@medctr.osu.edu
Study chairs or principal investigators
Antonius Miller, MD, Study Chair
Comprehensive Cancer Center of Wake Forest University
|
 |
|
